Filter by: patients
Home > Community Treatment Reports and Side Effects > Combigan Treatment Report
What is Combigan?

Combigan contains brimonidine, an alpha-blocker that reduces the amount of fluid in the eye, which decreases pressure inside the eye and timolol a beta-blocker that reduces pressure inside the eye. It is used to treat glaucoma or ocular hypertension.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Glaucoma 6 1 Efficacy_moderate
Other 1 0

See all 6 patients currently taking Combigan

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 1
None
 0

Commonly reported side effects, conditions, and hospitalizations associated with Combigan

Blurry vision 1
Burning sensation in eyes 1

Reported Dosages

  0.5 mL daily 2 other daily 5 mL daily 10 mL daily 20 mL daily
  1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Combigan (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe 1   Side effects too severe: 100%

See all 1 patient who’ve stopped taking Combigan

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Combigan

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Combigan

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Combigan

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Combigan

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of Combigan

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 1 100%
< $25
 0 0%

Report created on May 28, 2012.